BBUSvsBIB
JPMorgan BetaBuilders U.S. Equity ETF against ProShares Ultra Nasdaq Biotechnology — the fee, the flows, the book, and a year head-to-head.
Head to head
| BBUS | BIB | |
|---|---|---|
| Expense ratio | 0.020% | 0.95% |
| Assets | $9.6B | $96M |
| Net flow, 1 month | +$257M | +$2M |
| Net flow, 1 year | +$2.6B | −$8M |
| Return, YTD | +12.6% | +44.5% |
| Return, 1 year | +11.8% | +66.9% |
| Avg daily volume | 242K | 7K |
| Holdings | 575 | 229 |
| Listed | Mar 11, 2019 | Apr 9, 2010 |
| Options market | Yes | Yes |
MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS